


## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification<sup>4</sup> :</b>  <b>A61J 1/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 85/ 03432</b>  <b>(43) International Publication Date:</b> 15 August 1985 (15.08.85)
<b>(21) International Application Number:</b> PCT/BE85/00001 <b>(22) International Filing Date:</b> 23 January 1985 (23.01.85) <b>(31) Priority Application Number:</b> 578,908 <b>(32) Priority Date:</b> 10 February 1984 (10.02.84) <b>(33) Priority Country:</b> US  <b>(71) Applicant:</b> TRAVENOL EUROPEAN RESEARCH AND DEVELOPMENT CENTRE [BE/BE]; Parc Industriel, rue du Progrès 7, B-1400 Nivelles (BE). <b>(72) Inventors:</b> BOCQUET, Jacques, R. ; 27, avenue Eugene Isaye, B-1070 Bruxelles (BE). GOLDHABER, Richard, P. ; 12, Chemin des Catamouriaux, B-1410 Waterloo (BE). KERSTEN, Jean ; 259, Chaussée de Tournai, B-7931 Villers St. Amand (BE). MATHIAS, Jean-Marie ; 23, rue du Chêne, B-1400 Nivelles (BE). PEARSON, Stephen; 34520 North Hickory Court, Ingleside, IL 60041 (US).		<b>(74) Agent:</b> DeBRABANTER, Maurice; Bureau Vander Haeghen, avenue de la Toison d'Or, 63, B-1060 Brussels (BE).  <b>(81) Designated States:</b> AU, BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), JP, NL (European patent), SE (European patent).  <b>Published</b> <i>With international search report.          Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

**(54) Title:** CLOSED DRUG DELIVERY SYSTEM**(57) Abstract**

A sterile, closed drug delivery system (10) comprising a flexible container (12), a capsule (22) coupled to the flexible container (12) and a standard glass drug vial (36) positioned within the capsule (22). The flexible container (12) has a liquid diluent therein. The capsule (22) has supporting legs (32-35) which extend inwardly from the capsule (22) to support the vial (36) and also a highly flexible, pleated cap (28) which enables the drug vial (36) to be manually moved relative to the supporting legs (32-35). The capsule (22) is coupled to the flexible container (12) by means of a hollow spike (54) located within the capsule (22) and a frangible member (58) located within the flexible container (12), which frangible member (58) allows fluid passage only when it is broken. Manual pressing of the pleated cap (28) moves the drug vial downwardly onto the spike (54), piercing the stopper of the drug vial (36). Once the frangible member (58) is broken, there is sterile communication between the drug vial (36) and the liquid diluent contents of the flexible container (12).



***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GA	Gabon	MR	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BB	Barbados	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali		
FR	France				

CLOSED DRUG DELIVERY SYSTEMTECHNICAL FIELD

The present invention concerns a novel closed drug delivery system enabling a safe and easy reconstitution of a drug just prior to use.

BACKGROUND ART

5 Many drugs are mixed with a diluent before being delivered intravenously to a patient. The diluent may be, for example, a dextrose solution, a saline solution or even water. Many such drugs are supplied in powder form and packaged in glass vials. Other drugs, such as some used in  
10 chemotherapy, are packaged in glass vials in a liquid state.

Powdered drugs may be reconstituted in a wellknown manner, utilizing a syringe which is used to inject liquid into the vial for mixing, the syringe eventually withdrawing the mixed solution from the vial. When a drug must be di-  
15 luted before delivery to a patient, the drug is often injected into a container of diluent, where the container may be connected to an administration set for delivery to a patient. More specifically, the diluent is often packaged in glass bottles, or flexible plastic containers such as are  
20 sold under the names MINI-BAG<sup>TM</sup> and VIAFLEX<sup>®</sup> by Travenol Laboratories, Inc. of Deerfield, Illinois. These containers have administration ports for connection to an administration set which delivers the container contents from the container to the patient. The drug is typically added to the  
25 container through an injection site on the container.

Drugs may be packaged separately from the diluent for various reasons. One of the most important reasons is that some drugs do not retain their efficacy when mixed with a diluent and thus cannot be stored for any substantial  
30 period of time. In some instances the drug and diluent will not stay mixed for a significant length of time. Also, drugs are often packaged separately from the diluent because many firms which manufacture drugs are not engaged in the business of providing medical fluids in containers for intrave-  
35 nous delivery.

FEUILLE DE REMPLACEMENT

Therefore, a doctor, nurse, pharmacist or other medical personnel must mix the drug and diluent. This presents a number of problems. The reconstitution procedure is time consuming. The operator must provide  
5 the proper diluent and a syringe before beginning. Often the powdered drug is "caked" at the bottom of the vial. Thus, when liquid is injected into the vial from a syringe, the surface area of contact between the liquid and the powdered drug may be quite small  
10 initially, thus making the mixing procedure even more time consuming. Because of the limited vial volume, the increasing drug concentration in the diluent makes it harder to finish the reconstitution process. The operator may attempt to solve this by repeatedly  
15 injecting solution into the vial, mixing and withdrawing the solution but this makes necessary additional injections and movement of the syringe which increase the likelihood of contamination. Also, it is sometimes difficult to get all of the drug and/or  
20 liquid out of the vial, thus increasing the time required to perform the reconstitution procedure.

The reconstitution procedure should be performed under preferably sterile conditions. In addition to such a requirement making the operator justifiably more  
25 cautious and consuming more time, sterile conditions are often hard to maintain. In some instances, a laminar flow hood may be required under which the reconstitution procedure is performed.

Some drugs such as, for example, some chemotherapy  
30 drugs, are toxic. Exposure of the operator to the drugs during reconstitution may be dangerous, especially if the operator works with such drugs on a daily basis and is repeatedly exposed to them.

A further problem is that the reconstitution  
35 provides a source of confusion as to which container contains which drug, because the diluent container must

be marked with the drug with which it has been injected or at least the name of the patient to whom it should be delivered.

5 It can be seen that a closed system for separate storage of a drug and diluent would be most beneficial. Certain facts have until recently prohibited such a closed system on a commercially feasible, reasonably inexpensive basis, however. One factor which has made difficult the manufacture of a closed system having  
10 separate, selectively communicating compartments for a drug and a diluent has been the sterilization procedure. As an example, in the case of diluent in a flexible plastic container, the container with the diluent therein is sterilized by steam sterilization, or autoclaving. However, the heat generated during  
15 such a sterilization procedure would destroy the efficacy of many drugs. On the other hand, other sterilization means such as the use of ethylene oxide gas may not harm the drug but may harm the diluent. A system for sterilizing a drug and diluent separately  
20 and combining the two components into a single container having separate compartments for separate storage after sterilization is shown in a U.S. patent application in the name of William Schnell, entitled  
25 "Sterilized Liquid Mixing System," U.S. patent application Serial No. 365,940, filed April 6, 1982 and assigned to the assignee of the present invention.

These considerations mandate that, absent means to protect the drug and diluent during different  
30 sterilization steps, the system be formed by combining separate drug and diluent receptacles after they have been separately sterilized. This requires the manufacture of a sterile or at least an aseptic connection between the two receptacles. Sterile  
35 connectors are known, such as shown, for example, in U.S. Patent Nos. 4,157,723, 4,265,280 and 4,325,417,

all assigned to the assignee of the present invention. The connectors disclosed therein provide highly reliable, sterile connections. They do, however, employ a separate radiant energy source to make the connection and therefore a power supply to operate the energy source.

Another requirement of such a closed system is that it should prevent water vapor transmission from the receptacle holding the diluent to the receptacle holding the powdered drug. As discussed earlier, the storage of some powdered drugs with even a small amount of liquid destroys drug efficacy. Such a closed system should also be constructed in a manner which will facilitate easy and thorough mixing of the drug and the diluent.

In U.S. Patent Nos. 4,410,321 and 4,411,662, both assigned to the assignee of the present invention, a closed drug delivery system is disclosed, in which a drug and a diluent are separately stored and selectively mixed used sterile conditions. In the illustrative embodiments, a sterile coupling is utilized which includes a permanently affixed molded junction. In some instances, however, it may be desirable to avoid the use of a permanently affixed molded junction, as part of the sterile coupling. To this end, we have developed a closed drug delivery system that enjoys most of the benefits of the system disclosed in U.S. Patent Nos. 4,410,321 and 4,411,662, yet avoids the use of a permanently affixed molded junction, allows safe and easy reconstitution of a drug just prior to use, and is relatively simple in construction and easy to manufacture.

#### DISCLOSURE OF THE INVENTION

In accordance with the present invention, a closed drug delivery system is provided which comprises a flexible container, a capsule coupled to the flexible

container and a drug vial. The flexible container has a liquid diluent therein and a delivery outlet. The capsule that is coupled to the flexible container has means for supporting the drug vial and has flexible means for enabling movement of the drug vial relative to the supporting means. The drug vial has a drug therein, adapted to be mixed with the diluent. The drug vial is supported by the supporting means and is adapted for engagement by the flexible means. Means couple the capsule to the interior of the flexible container, with the coupling means including means for communicating with the interior of the drug vial. The communicating means is out of communication with the interior of the vial when the vial is in a first position supported by the supporting means. The communicating means is in communication with the interior of the vial when the vial has been moved relative to the supporting means and the vial is in another position within the capsule.

In the illustrative embodiment, the capsule has a relatively rigid bottom and side walls and the flexible means comprises a flexible member that is sealed at the top of the side walls. The flexible member is substantially deformable to enable manual downward movement thereof. The flexible member includes a plurality of pleats surrounding a planar central portion, with the flexible member being sealed to the side walls adjacent the periphery of the flexible member. The flexible member has a generally circular outline and the capsule carries means for enabling hanging of the capsule.

In the illustrative embodiment, the drug vial comprises a standard glass drug vial bottle having a pierceable stopper retained by a metal band. The communicating means comprises a spike for piercing the stopper when the vial is moved onto the spike.

In the illustrative embodiment, the supporting means comprise a plurality of legs extending inwardly from the capsule. In one embodiment, the legs extend upwardly from the bottom of the capsule while in  
5 another embodiment the legs extend radially inwardly from the side walls of the capsule.

In the illustrative embodiment, the coupling means include a frangible member preventing fluid flow unless the frangible member is broken.

10 A more detailed explanation of the invention is provided in the following description and claims, and is illustrated in the accompanying drawings.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a perspective view, partially broken  
15 for clarity and also showing an opened capsule for clarity, of a closed drug delivery system constructed in accordance with the principles of the present invention.

Figure 2 is a cross-sectional elevation, taken  
20 along the plane of the line 2-2 of Figure 1, but showing the top of the capsule in its normal, sealed position.

Figure 3 is a cross-sectional elevation, similar to Figure 2, but showing the drug vial being moved.

25 Figure 4 is a cross-sectional elevation, similar to Figure 2, but showing a modified embodiment of the present invention.

#### DETAILED DESCRIPTION OF THE ILLUSTRATIVE EMBODIMENTS

Referring to Figures 1 and 2, a drug delivery  
30 system 10 is shown therein. System 10 includes flexible container 12, preferably formed from flexible plastic (e.g., polyvinyl chloride) sheets having peripheral seals 13, 14, 15 and 16 to define a compressible chamber 18. Chamber 18 has a liquid  
35 diluent, such as a dextrose solution, a saline solution, or water therein. A delivery outlet port 20

communicates with chamber 18 and extends from flexible container 12 at the lowest location thereof. A portion of port 20 is sealed to the container by sealing the lower ends 21 of the plastic sheets against each other and around port 20.

A plastic capsule 22 is coupled to flexible container 12. Capsule 22 has a generally cylindrical configuration, with a bottom 23, side walls 24, and upper rim 26, a pleated top cap 28, and a pair of generally D-shaped hanger members 29, 30. The capsule bottom 23, side walls 24 which are formed in a generally circular configuration, rim 26 and hanger members 29, 30 are formed in a one-piece molded construction, while pleated cap 28 is formed separately and is subsequently bonded to rim 26. While cap 28 is illustrated in Figure 1 as being unattached to rim 26, in use the cap 28 has been bonded to rim 26 and the drug delivery system is a closed, sterile system as will be discussed below.

The bottom 23 and side walls 24 of capsule 22 are relatively rigid, and supporting means in the form of four legs 32, 33, 34 and 35 extend inwardly from side walls 24 of the capsule at the bottom thereof. Legs 32-35 support a standard glass drug vial bottle 36 which is located within capsule 22. Vial 36 contains a powdered or liquid drug and as is conventional, includes a neck 38 which extends to a rubber-stopped end 40 with the rubber, pierceable stopper being retained by a metal band 42.

Cap 28 is generally circular and includes three concentric pleats 44 surrounding a planar central portion 46. The circumferential portion 48 of cap 28 is sealed to capsule rim 26 by sonic welding or by use of a hot die. Cap 28 overlies bottom 50 of vial 36 and is spaced a short distance therefrom, so that when planar portion 46 of cap 28 is manually pressed, it

will force vial 36 to move downwardly as will be explained in more detail below.

5 Capsule 22 includes an extending outer tube 52 which surrounds a plastic hub 57. Hub 57 is overmolded around a one-piece stainless steel needle 54 having a spike tip 55 extending into capsule 22 centrally thereof. The other end 56 of hollow needle 54 extends into chamber 18 near the top of the chamber. The lower portion of needle 54 is surrounded by a tubular portion 10 53 of a plastic frangible member 58. Tubular portion 53 of the frangible member 58 is secured to needle 54 by either an interference fit between the needle and the tubular portion 53 or by using adhesive or by using adhesive with an interference fit.

15 Frangible member 58 comprises the tubular portion 53, a closed fracturable section 60 and ribs 63, similar to the frangible member disclosed in U.S. Patent No. 4,340,049. When broken at section 60, the tubular portion 53 will be open at its bottom.

20 The fracturable member 58 is surrounded by a sleeve 52a which defines two side ports 61 disposed relatively high up in the chamber 18. The sleeve 52a is connected to container 12 by means of heat seal 14 which secures the outer sheets forming container 12 to sleeve 52a when heat seal 14 is applied. 25

The use of side ports 61 disposed relatively high up in chamber 18 towards seal 14 increases the size of the flow path of fluid, either gas or liquid, going through needle 54 into chamber 18, so that liquid or 30 air passing through the end 56 of needle 54 can exit end 65 of tube 52a or can exit from ports 61. Secondly, ports 61 allow for the easy passage of air in chamber 18 back into vial 36. By providing ports 61 relatively high up in the chamber, less air may be maintained in 35 the chamber during manufacture. In other words, container 12 may be manufactured with a higher liquid

level. Thus side ports 61 in tube 52a allow air to be passed back from container 12 into vial 36 in order to pressurize any liquid in vial 36 for returning the liquid back into the chamber 18.

5        Now referring to Figure 3, the operation of mixing the drug within vial 36 with the diluent within chamber 18 is as follows. Manual thumb pressure is exerted against planar central member 46 of cap 28 to deform the cap downwardly as illustrated in Figure 3. This  
10       will push vial 36 downwardly as illustrated, and legs 32-35 will give resiliently to enable this downward movement so that spike 55 will pierce the rubber stopper at the end 40 of vial 36. The operator will then manually bend the frangible member 58 to break it  
15       around fracturable section 60 and a path will then be opened whereby hollow needle 54 will communicate with the interior of chamber 18 and with the interior of vial 36. Flexible container 12 can then be squeezed appropriately to drive the diluent into vial 36 where  
20       it will be mixed with the drug that is within vial 36.

Figure 4 shows a closed drug delivery system 10' that is similar in most respects to the system of Figures 1-3, except that in the Figure 4 embodiment, four legs 62 (only three of the legs are shown) extend  
25       upwardly from the bottom 23 of capsule 22, to support vial 36. In addition, instead of using a hollow stainless steel needle as in the Figures 1-3 embodiment, a hollow, rigid plastic spike 64 is utilized. One end 66 of spike 64 communicates with the  
30       interior of capsule 22 while the other end 68 of spike 64 communicates with the interior of chamber 18 once the frangible member 58 is broken.

In the manufacture of the system illustrated in Figures 1-3 and the Figure 4 system, the flexible  
35       container 12 with the diluent and the capsule 22 coupled to flexible container 12, but without cap 28

and vial 36, are steam sterilized. The steam sterilized unit, cap 28 and vial 36 are placed in a room that is then sterilized with gas. Once this gas sterilization is accomplished, vial 36 is inserted into  
5 the capsule and the cap 28 is hermetically bonded to lip 26 by sonic welding or by the use of a hot die. The operation with the vial and bonding of the cap can be accomplished using glove portholes or by a person in a "clean suit."

10 It can be seen that a sterile, closed drug delivery system has been provided which does not require a permanently molded junction, and which allows a safe and easy reconstitution of a drug just prior to use.

15 Although illustrative embodiments of the invention have been shown and described, it is to be understood that various modifications and substitutions may be made by those skilled in the art without departing from the novel spirit and scope of the present invention.

C L A I M S

1. A closed drug delivery system (10,10') which comprises :

5 a flexible container (12) having a liquid diluent therein, said flexible container having a delivery outlet (20) ;

a capsule (22) coupled to said flexible container (12), said capsule (22) having means (32-35;62) for  
10 supporting a drug vial (36) and flexible means (28) for enabling movement of the drug vial (36) relative to the supporting means (32-35;62) ;

the drug vial (36) having a drug therein adapted to be mixed with said diluent, said drug vial (36)  
15 being supported by said supporting means (32-35;62) and being adapted for engagement by said flexible means (28) ;

means (52-58) coupling said capsule (22) to the interior of said flexible container (12), said coupling  
20 means (52-58) including means (55,66) for communicating with the interior of the drug vial (36), said communicating means (55,66) being out of communication with the interior of the drug vial (36) when the vial (36) is in a first position supported by said supporting  
25 means (32-35;62), said communicating means (55,66) being in communication with the interior of the drug vial (36) when the vial (36) has been moved relative to said supporting means (32-35;62) and the vial (36) is in another position within said capsule (22).

30 2. A system as described in claim 1, said flexible container (12) comprising a sealed vinyl container and said delivery outlet (20) is at a lowest location of the container.

3. A system as described in claim 1, said capsule (22) having a relatively rigid bottom (23) and side walls (24), and said flexible means (28) comprising a flexible member (28) that is sealed at the top of the side walls (24), said flexible member (28) being substantially deformable to enable manual downward movement thereof.

4. A system as described in claim 3, said flexible member (28) including a plurality of pleats (44) surrounding a planar central portion (46), with the flexible member (28) being sealed to the side walls (24) adjacent the periphery of the flexible member (28).

5. A system as described in claim 3, said flexible member (28) having a generally circular outline and said capsule (22) carrying means (29,30) for enabling hanging of the capsule (22).

6. A system as described in claim 1, said capsule (22) having side walls (24) formed in a generally circular configuration, and said flexible means (28) comprising a generally circular flexible member (28) sealed at the top of the side walls (24) and being substantially deformable to enable manual downward movement thereof.

7. A system as described in claim 6, said flexible member (28) including a plurality of pleats (44) surrounding a planar central portion (46), with the flexible member (28) being sealed to the side walls (24) adjacent the periphery of the flexible member (28).

8. A system as described in claim 1, said drug vial (36) comprising a standard glass drug vial bottle (36) having a pierceable stopper (40) retained by a metal band (42), said communicating means (55,66)

comprising a spike (55,66) for piercing said stopper (40) when the vial (36) is moved onto the spike (55,66).

5 9. A system as described in claim 1, said drug vial (36) having a pierceable stopper (40), said communicating means (55,66) comprising a spike (55,66) for piercing said stopper (40) when the vial (16) is moved onto the spike (55,66).

10 10. A system as described in claim 1, said capsule (22) having a bottom (23) and side walls (24) with said supporting means (32-35;62) comprising a plurality of legs (32-35;62) extending inwardly from the capsule (22).

15 11. A system as described in claim 10, said legs (32-35;62) extending upwardly from the bottom (23) of the capsule (22).

12. A system as described in claim 10, said legs (32-35) extending radially inwardly from the side walls (24) of the capsule (22).

20 13. A system as described in claim 1, said coupling (52-58) means including a frangible member (58) preventing fluid flow unless the frangible member (58) is broken.

25 14. A system as described in claim 1, said capsule (22) comprising a relatively rigid plastic housing and said flexible means (28) comprising a plastic bellows cap (28) sealingly covering the plastic housing, the plastic bellows cap (28) being substantially deformable to enable manual downward movement thereof.

30 15. A system as described in claim 1, said flexible container (12), said capsule (22) and said coupling means (52-58) having sterile interiors whereby the drug delivery system is sterile.

16. A closed drug delivery system which comprises

a flexible container (12) having a liquid diluent therein, said flexible container (12) having a delivery outlet (20) ;

5 said flexible container (12) comprising a sealed vinyl container and said delivery outlet (20) being at a lowest location of the container (12) ;

a capsule (22) coupled to said flexible container (12), said capsule (22) having means (32-35;62) for supporting a drug vial (36) and flexible means (28) for  
10 enabling movement of the drug vial (36) relative to the supporting means (32-35;62) ;

said capsule (22) having a relatively rigid bottom (23) and side walls (24), and said flexible means (28) comprising a flexible member (28) that is sealed at the  
15 top of the side walls (24), said flexible member (28) being substantially deformable to enable manual downward movement thereof ;

said flexible member (28) including a plurality of pleats (44) surrounding a planar central portion (46),  
20 with the flexible member (28) being sealed to the side walls (24) adjacent the periphery of the flexible member (28) ;

said flexible member (28) having a generally circular outline and said capsule (22) carrying means  
25 (29,30) for enabling hanging of the capsule ;

a drug vial (36) having a drug therein adapted to be mixed with said diluent, said drug vial (36) being supported by said supporting means (32-35;62) and being adapted for engagement by said flexible member (28) ;

30 means (52-58) coupling said capsule (22) to the interior of said flexible container (12), said coupling means (52-58) including means (55,56) for communicating with the interior of the drug vial (36), said communicating means (55,56) being out of communication with

the interior of the vial (36) when the vial (36) is in a first position supported by said supporting means (32-35;62), said communicating means (55,56) being in communication with the interior of the vial (36) when  
5 the vial (36) has been moved relative to said supporting means (32-35;62) and the vial (36) is in another position within said capsule (22) ;

said drug vial (36) having a pierceable stopper (40), said communicating means (55,56) comprising a  
10 spike (55,56) for piercing said stopper (40) when the vial (36) is moved onto the spike (55,56) ;

said supporting means (32-35;62) comprising a plurality of legs (32-35;62) extending inwardly from the capsule (22) ; and

15 said coupling means (52-58) including a frangible member (58) preventing fluid flow unless the frangible member (58) is broken.

17. A drug delivery system which comprises :  
a flexible container (12) having a liquid diluent  
20 therein ;

a capsule (22) coupled to said flexible container (12), said capsule (22) having means (32-35;62) for supporting a drug vial (36) and flexible means (28) for enabling movement of the drug vial (36) relative to the  
25 supporting means (32-35;62) ;

means (52-58) coupling said capsule (22) to the interior of said flexible container (28), said coupling means (52-58) including means (55,56) for communicating with the interior of the drug vial (36), said communicating means (55,56) being out of communication with  
30 the interior of the vial (36) when the vial (36) is in a first position supported by said supporting means (32-35;62), said communicating means (55,56) being in communication with the interior of the vial (36) when

the vial (36) has been moved relative to said supporting means (32-35;62) and the vial (36) is in another position within said capsule (22).

18. A system as described in claim 17, said  
5 flexible container (12) comprising a sealed vinyl container (12) having a delivery outlet (20) at a lowest location of the container (12).

19. A system as described in claim 17, said  
10 capsule (22) having a relatively rigid bottom (23) and side walls (24), and said flexible means (28) comprising a flexible member (28) that is sealed at the top of the side walls (24), said flexible means (28) being substantially deformable to enable manual downward movement thereof.

15 20. A system as described in claim 19, said flexible member (28) including a plurality of pleats (44) surrounding a planar central portion (46), with the flexible member (28) being sealed to the side walls (24) adjacent the periphery of the flexible member  
20 (28).

21. A system as described in claim 20, said flexible member (28) having a generally circular outline and said capsule (22) carrying means (29,30) for enabling hanging of the capsule (22).

25 22. A system as described in claim 17, said capsule (22) having side walls (24) formed in a generally circular configuration, and said flexible means (28) comprising a generally circular flexible member (28) sealed at the top of the side walls (24)  
30 and being substantially deformable to enable manual downward movement thereof.

23. A system as described in claim 17, including a drug vial (36) having a drug therein adapted to be mixed with said diluent, said drug vial (36) being

supported by said supporting means (32-35;62) and being adapted for engagement by said flexible means (28), said drug vial (36) comprising a standard glass drug vial bottle (36) having a pierceable stopper (40)

5 retained by a metal band (42), said communicating means (55,56) comprising a spike (55,56) for piercing said stopper (40) when the vial (36) is moved onto the spike (55,56).

24. A system as described in claim 17, including  
10 a drug vial (36) having a drug therein adapted to be mixed with said diluent, said drug vial (36) being supported by said supporting means (32-35;62) and being adapted for engagement by said flexible means (28), said drug vial (36) having a pierceable stopper (40),  
15 said communicating means (55,56) comprising a spike (55,56) for piercing said stopper (40) when the vial (36) is moved onto the spike (55,56).

25. A system as described in claim 17, said capsule (22) having a bottom (23) and side walls (24)  
20 with said supporting means (32-35;62) comprising a plurality of legs (32-35;62) extending inwardly from the capsule (22).

26. A system as described in claim 17, said coupling means (52,58) including a frangible member  
25 (58) preventing fluid flow unless the frangible member (58) is broken.

27. A system as described in claim 17, said capsule (22) comprising a relatively rigid plastic housing and said flexible means (28) comprising a  
30 plastic bellows cap (28) sealingly covering the plastic housing, the plastic bellows cap (28) being substantially deformable to enable manual downward movement thereof.

FIG. 1




FIG. 2




FIG. 3





FIG. 4



# INTERNATIONAL SEARCH REPORT

International Application No. PCT/BE 85/00001

## I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) \*

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC<sup>4</sup>: A 61 J 1/00

## II. FIELDS SEARCHED

Minimum Documentation Searched <sup>7</sup>

Classification System

Classification Symbols

IPC<sup>4</sup>      A 61 J; B 65 D

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are Included in the Fields Searched \*

## III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>8</sup>

Category <sup>9</sup>	Citation of Document, <sup>11</sup> with Indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	WO, A, 83/03587 (BAXTER TRAVENOL LAB.) 27 October 1983, see page 1, lines 6-10; page 5, lines 5-13, 23-36; page 6, lines 27-34; page 8, lines 34-36; page 9, lines 1-13; page 11, lines 35, 36; page 12, lines 1-3; figures 5,7,7A --	1,2,8,9, 13,15,16, 17,18,23, 24,26
Y	EP, A, 0091310 (BAXTER TRAVENOL LAB.) 12 October 1983, see page 5, lines 1-7; page 9, lines 1-9, 33,34; page 10, lines 1-13; page 11, lines 9-34; page 12, lines 1-8; page 18, lines 26-34; page 19, lines 1-32; page 20, lines 9-14; figures 1,6,7,8 & US, A, 4410321 (cited in the application) --	1,2,8,9, 13,15,16, 17,18,23, 24,26 "
A	US, A, 2362025 (PRICE) 7 November 1944, see page 1, left-hand column, lines 38-46; right-hand column, lines 38-55; page 2, left-hand column, lines 1-37; figures 1,2 --	1

\* Special categories of cited documents: <sup>10</sup>

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Δ" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search  
22nd April 1985

Date of Mailing of this International Search Report

06 JUN 1985

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

G.L.M. Kruvdenberg

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	GB, A, 2096464 (THE WEST CO.) 20 October 1982, see page 2, lines 61-65; figure 5  -----	5

## ANNEX TO THE INTERNATIONAL SEARCH REPORT OF

INTERNATIONAL APPLICATION NO.

PCT/BE 8500001 (SA 8795)

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 29/05/85

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A- 8303587	27/10/83	AU-A- 1511583	04/11/83
		EP-A- 0105330	18/04/84
		US-A- 4467588	28/08/84
EP-A- 0091310	12/10/83	US-A- 4410321	18/10/83
		WO-A- 8303586	27/10/83
		AU-A- 1475083	04/11/83
US-A- 2362025		None	
GB-A- 2096464	20/10/82	FR-A- 2503565	15/10/82
		DE-A- 3213072	11/11/82
		US-A- 4479578	30/10/84

For more details about this annex :  
see Official Journal of the European Patent Office, No. 12/82